Ethics, error, and initial trials of efficacy

Science Translational Medicine

Volumn 5, Issue 184, 2013, Pages

  Hey, Spencer Phillips ^a   Kimmelman, Jonathan ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; RANDOMIZATION; RESEARCH ETHICS; RESOURCE ALLOCATION; SHORT SURVEY; STUDY DESIGN; SYSTEMATIC ERROR;

CLINICAL TRIALS, PHASE II AS TOPIC; ETHICS, RESEARCH;

EID: 84878300288     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3005684     Document Type: Short Survey

References (10)

1. M. I. Zia, L. L. Siu, G. R. Pond, E. X. Chen, Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J. Clin. Oncol. 23, 6982-6991 (2005).
2. A. Stone, C. Wheeler, A. Barge, Improving the design of phase II trials of cytostatic anticancer agents. Contemp. Clin. Trials 28, 138-145 (2007).
3. M. R. Sharma, M. L. Maitland, M. J. Ratain, Other paradigms: Better treatments are identified by better trials: The value of randomized phase II studies. Cancer J. 15, 426-430 (2009).
4. J. Kimmelman, A. J. London, Predicting harms and benefits in translational trials: Ethics, evidence, and uncertainty. PLoS Med. 8, e1001010 (2011).
5. B. Djulbegovic, A. Kumar, A. Magazin, A. T. Schroen, H. Soares, I. Hozo, M. Clarke, D. Sargent, M. J. Schell, Optimism bias leads to inconclusive results-an empirical study. J. Clin. Epidemiol. 64, 583-593 (2011).
6. A. J. London, J. Kimmelman, M. E. Emborg, Research ethics. Beyond access vs. protection in trials of innovative therapies. Science 328, 829-830 (2010).
7. N. Bristol, Should terminally ill patients have access to phase I drugs? Lancet 369, 815-816 (2007).
8. A. Von Eschenbach, "Medical innovation: How the U.S. can retain its lead." Wall Street Journal, 14 February 2012, Opinion.
9. P. B. Gilbert, Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or concepts. Stat. Med. 29, 1061-1071 (2010).
10. P. P. J. Phillips, S. H. Gillespie, M. Boeree, N. Heinrich, R. Aarnoutse, T. McHugh, M. Pletschette, C. Lienhardt, R. Hafner, C. Mgone, A. Zumla, A. J. Nunn, M. Hoelscher, Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J. Infect. Dis. 205, (suppl. 2), S250-S257 (2012).